AtheroNova is an early-stage biotech company focused on the discovery, research, development and licensing of novel compounds designed to reduce or eliminate atherosclerotic plaque deposits. The company is currently completing two additional studies to validate the efficacy findings of its initial study and prepare for upcoming human trials. AtheroNova plans to develop multiple applications for its compounds. For more information visit the company’s Web site at: www.atheronova.com.

Aegis Capital Corp. is a full service retail and institutional broker-dealer located in New York City. Aegis Capital’s management is committed to providing the highest level of service to its clients. The firm realizes this goal by running an independent, conflict-free platform that is focused on enhancing the goals of clients by bringing unencumbered advice, which enables them to freely create a plan centered on each client. For more information on Aegis Capital, visit www.aegiscapcorp.com.

Let us hear your thoughts below: